Catalent Marks 40 Years in Japan with New Investments and Country Leader - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Marks 40 Years in Japan with New Investments and Country Leader



Catalent now in its 40th year of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products in the Japanese market and has appointed Tadahiro Matsumura as Country Leader. Based in Catalent’s Tokyo office, Matsumura will be responsible for driving growth through business development activities in Japan and the surrounding region.

In addition, the company has opened a laboratory at its Kakegawa, Japan site to provide proof-of-concept support and feasibility studies for Catalent’s Zydis Orally Dispersible Tablet (ODT) technology and will also expand manufacturing capacity for its OptiGel Micro softgel technology. Zydis ODT is a freeze-dried oral dosage form that disperses in the mouth, requiring no water. The new Zydis laboratories, which will be officially opened as part of the 40th anniversary celebrations in September, is being constructed within the existing 107,000 square-foot Kakegawa facility. Catalent’s OptiGel Micro Technology uses a droplet, streamline flow that results in spherical capsules. These capsules can be sized from 1-7mm, which allows for smaller capsules to be produced when compared to the traditional rotary die process.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here